Alterity Therapeutics Ltd (ATHE)vsVertex Pharmaceuticals Inc (VRTX)
ATHE
Alterity Therapeutics Ltd
$4.02
-2.52%
HEALTHCARE · Cap: $88.31M
VRTX
Vertex Pharmaceuticals Inc
$447.54
+0.76%
HEALTHCARE · Cap: $114.99B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 184006% more annual revenue ($12.22B vs $6.64M). VRTX leads profitability with a 35.5% profit margin vs -219.9%. VRTX earns a higher WallStSmart Score of 68/100 (B-).
ATHE
Avoid26
out of 100
Grade: F
VRTX
Strong Buy68
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ATHE.
Margin of Safety
+54.3%
Fair Value
$955.66
Current Price
$447.54
$508.12 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 74.6% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Keeps 36 of every $100 in revenue as profit
Strong operational efficiency at 38.1%
Earnings expanding 61.4% YoY
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 22 in profit
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -46.4% — below average capital efficiency
Distress zone — elevated risk
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ATHE
The strongest argument for ATHE centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 74.6% demonstrates continued momentum.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 35.5% and operating margin at 38.1%.
Bear Case : ATHE
The primary concerns for ATHE are EPS Growth, Market Cap, Return on Equity.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
ATHE profiles as a hypergrowth stock while VRTX is a mature play — different risk/reward profiles.
ATHE is growing revenue faster at 74.6% — sustainability is the question.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
VRTX scores higher overall (68/100 vs 26/100), backed by strong 35.5% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alterity Therapeutics Ltd
HEALTHCARE · BIOTECHNOLOGY · USA
Alterity Therapeutics Limited researches and develops therapeutic drugs for the treatment of Parkinson's disease and other neurodegenerative diseases in Australia. The company is headquartered in Melbourne, Australia.
Visit Website →Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?